Literature DB >> 33194081

Long non-coding RNA NCK1-AS1 promotes the proliferation, migration and invasion of non-small cell lung cancer cells by acting as a ceRNA of miR-137.

Jianxin Li1, Xinglong Wu2, Wenxia Cao3, Jianqiang Zhao4.   

Abstract

Long noncoding RNAs (lncRNAs) have been shown to play important roles in carcinogenesis and progression. In this study, we mainly investigate the potential influence of lncRNA NCK1 antisense RNA 1 (NCK1-AS1) on the progression of non-small cell lung cancer (NSCLC). RT-PCR was performed to determine the expression of NCK1-AS1 and miR-137 in NSCLC specimens and cell lines. The clinical significance of NCK1-AS1 in 148 patients was analyzed statistically. The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of NCK1-AS1 and miR-137. Regulatory effects of NCK1-AS1 on proliferative, colony formation abilities, metastasis and apoptosis of SK-MES-1 and H1299 cells were assessed through a series of functional experiments. RNA-pull down and Dual-Luciferase reporter assay was performed to verify the sponge effect of NCK1-AS1 on miR-137. We observed that NCK1-AS1 expression was upregulated, while miR-137 expression was down-regulated in NSCLC specimens and cell lines. Increased NCK1-AS1 expression was positively correlated with TNM stage and lymph node metastasis and poor clinical outcome. The diagnostic value of NCK1-AS1 and miR-137 expression was also confirmed. Functionally, knockdown of NCK1-AS1 suppressed the proliferation, migration and invasion of NSCLC cells, and promoted apoptosis. Moreover, NCK1-AS1 was able to adsorb miR-137 via a sponge effect. Overall, our findings suggested that NCK1-AS1 may be a candidate biomarker and a target for new therapies in NSCLC patients. AJTR
Copyright © 2020.

Entities:  

Keywords:  LncRNA NCK1-AS1; NSCLC; biomarker; metastasis; miR-137

Year:  2020        PMID: 33194081      PMCID: PMC7653585     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  38 in total

Review 1.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

Authors:  Lais Osmani; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Semin Cancer Biol       Date:  2017-11-26       Impact factor: 15.707

Review 2.  Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapy.

Authors:  Branislav Jeremić
Journal:  Clin Lung Cancer       Date:  2014-09-28       Impact factor: 4.785

Review 3.  Computational Methods for Predicting ncRNA-protein Interactions.

Authors:  Shao-Wu Zhang; Xiao-Nan Fan
Journal:  Med Chem       Date:  2017       Impact factor: 2.745

4.  Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer.

Authors:  Nan Jiang; Xiaodan Meng; Hongchao Mi; Yidi Chi; Shenghui Li; Zeyu Jin; Hui Tian; Jinxian He; Weiyu Shen; Haihua Tian; Jinchang Pan; Shuai Fang; Xiaofeng Jin; Chengwei Zhou; Zhaohui Gong
Journal:  Clin Chim Acta       Date:  2018-07-17       Impact factor: 3.786

5.  MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.

Authors:  Feiyu Chen; Na Luo; Yu Hu; Xin Li; Kejing Zhang
Journal:  Cell Physiol Biochem       Date:  2018-07-05

6.  Knockdown of long non-coding RNA XIST inhibits cell viability and invasion by regulating miR-137/PXN axis in non-small cell lung cancer.

Authors:  Huijuan Jiang; Hongzhi Zhang; Xigang Hu; Wenbo Li
Journal:  Int J Biol Macromol       Date:  2018-01-11       Impact factor: 6.953

7.  miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation.

Authors:  Wei Zhang; Jo-Hsin Chen; Tianjiao Shan; Irene Aguilera-Barrantes; Li-Shu Wang; Tim Hui-Ming Huang; Janet S Rader; Xiugui Sheng; Yi-Wen Huang
Journal:  Lab Invest       Date:  2018-06-28       Impact factor: 5.662

8.  Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis.

Authors:  Xi Zhuang; Houchao Tong; Yu Ding; Luyao Wu; Jingsheng Cai; Yan Si; Hao Zhang; Meiping Shen
Journal:  Cell Death Dis       Date:  2019-08-14       Impact factor: 8.469

9.  LncRNA NCK1-AS1 promotes proliferation and induces cell cycle progression by crosstalk NCK1-AS1/miR-6857/CDK1 pathway.

Authors:  Haiyu Li; Yongqin Jia; Junning Cheng; Geli Liu; Fangzhou Song
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

10.  LncRNA LINC00662 promotes colon cancer tumor growth and metastasis by competitively binding with miR-340-5p to regulate CLDN8/IL22 co-expression and activating ERK signaling pathway.

Authors:  Bo Cheng; Aimei Rong; Quanbo Zhou; Wenlu Li
Journal:  J Exp Clin Cancer Res       Date:  2020-01-03
View more
  5 in total

Review 1.  LncRNA NCK1-AS1-mediated regulatory functions in human diseases.

Authors:  Yingfan Wang; Jie Pan; Zongzong Sun
Journal:  Clin Transl Oncol       Date:  2022-09-21       Impact factor: 3.340

2.  LncRNA NCK1-AS1 Promotes Malignant Cellular Phenotypes of Laryngeal Squamous Cell Carcinoma via miR-137/NCK1 Axis.

Authors:  Lanlan Wan; Dongsheng Gu; Xin Jin
Journal:  Mol Biotechnol       Date:  2022-02-26       Impact factor: 2.860

3.  lncRNA RP11-10A14.5: a potential prognosis biomarker for LUAD through regulation on proliferation and metastasis.

Authors:  Zhijie Lin; Fenglan Feng; Jiaming Liang; Haikang Zeng; Jin Li
Journal:  Discov Oncol       Date:  2022-05-16

4.  Long non‑coding RNA LINC01748 exerts carcinogenic effects in non‑small cell lung cancer cell lines by regulating the microRNA‑520a‑5p/HMGA1 axis.

Authors:  Yinling Tan; Fengxia Xu; Lingling Xu; Jianying Cui
Journal:  Int J Mol Med       Date:  2021-12-31       Impact factor: 4.101

5.  Long noncoding RNA HOXC-AS3 interacts with CDK2 to promote proliferation in hepatocellular carcinoma.

Authors:  Chen Su; Weijian Wang; Jie Mo; Furong Liu; Hongwei Zhang; Yachong Liu; Xiaoping Chen; Zhibin Liao; Bixiang Zhang; Peng Zhu
Journal:  Biomark Res       Date:  2022-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.